Cancer Family
Thoracic Neoplasm
CI-CAN-00000054Explore in graph →
Non-malignant2,893 active trials51 approved drugs626 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000054Explore in graph →
Clinical trials
12,163 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03490890 | Microwave Ablation in Ground Glass Nodules | unknown | Phase 2 | 200 | Shandong Provincial HospitalOTHER_GOV | 1 | Apr 9, 2018 | clinicaltrials |
| NCT03486496 | Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR Mutation(Geber) | unknown | Phase 2 | 50 | Fujian Cancer HospitalOTHER_GOV | 1 | Apr 3, 2018 | clinicaltrials |
| NCT02758587 | Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1) | unknown | Phase 1 / Phase 2 | 59 | NHS Greater Glasgow and ClydeOTHER | 1 | Mar 19, 2018 | clinicaltrials |
| NCT03466827 | Selinexor in Patients With Advanced Thymoma and Thymic Carcinoma(TET-SEL) | unknown | Phase 2 | 25 | Morten Mau-SoerensenOTHER | 2 | Mar 15, 2018 | clinicaltrials |
| NCT03460275 | Osimertinib as First-line Therapy for Patients With Late-stage Lung Cancer | unknown | Phase 2 | 100 | Sun Yat-sen UniversityOTHER | 1 | Mar 9, 2018 | clinicaltrials |
| NCT03461185 | Anti-angiogenesis Combine With EGFR-TKI in Advanced Non-squamous Non Small Cell Lung Cancer | unknown | Phase 2 | 100 | Xinqiao Hospital of ChongqingOTHER | 1 | Mar 9, 2018 | clinicaltrials |
| NCT03384667 | Maekmoondong-tang on Post-operative Cough in Patients With Lung Cancer | unknown | Phase 2 / Phase 3 | 96 | Seong-Gyu KoOTHER | 1 | Feb 28, 2018 | clinicaltrials |
| NCT03446911 | Combining SBRT and Immunotherapy in Early Stage NSCLC Patients Planned for Surgery | unknown | Phase 1 / Phase 2 | 20 | Amsterdam UMC, location VUmcOTHER | 0 | Feb 27, 2018 | clinicaltrials |
| NCT03424759 | Uncommon EGFR AZD9291 | unknown | Phase 2 | 37 | Samsung Medical CenterOTHER | 1 | Feb 7, 2018 | clinicaltrials |
| NCT03416231 | Apatinib Plus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer(NSCLC) | unknown | Phase 2 | 20 | Affiliated Hospital of North Sichuan Medical CollegeOTHER | 1 | Jan 31, 2018 | clinicaltrials |
| NCT03411967 | Apatinib in Combination With Docetaxel for Patients With Advanced NSCLC | unknown | Phase 2 | 20 | Zigong No.1 Peoples HospitalOTHER | 0 | Jan 26, 2018 | clinicaltrials |
| NCT02734524 | A Clinical Research of NK Cell Infusion Combined With Chemotherapy in the Treatment of Non-small Cell Lung Cancer | unknown | Phase 2 | 104 | Southwest Hospital, ChinaOTHER | 1 | Jan 23, 2018 | clinicaltrials |
| NCT02852083 | A Trial With Metronomic Low-dose Treosulfan, Pioglitazone and Clarithromycin Versus Standard Treatment in NSCLC(ModuLung) | unknown | Phase 2 | 86 | University Hospital RegensburgOTHER | 1 | Jan 18, 2018 | clinicaltrials |
| NCT03127319 | A Study of Apatinib Plus Docetaxel for Treatment of Advanced Non-squamous Non-small Cell Lung Cancer With Bone Metastases | unknown | Phase 2 | 40 | Affiliated Hospital of Hebei UniversityOTHER | 1 | Jan 17, 2018 | clinicaltrials |
| NCT03399669 | The Continuation of Gefitinib Treatment Beyond Progression in Non-small Cell Lung Cancer Patients With EGFR Mutation | unknown | Phase 2 | 100 | Samsung Medical CenterOTHER | 1 | Jan 16, 2018 | clinicaltrials |
| NCT03389256 | Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC | unknown | Phase 2 | 144 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Jan 3, 2018 | clinicaltrials |
| NCT02410369 | Study of S-588410 After Adjuvant Chemotherapy for Completely Resected Non-small- Cell Lung Cancer | unknown | Phase 2 | 60 | Tokyo UniversityOTHER | 1 | Dec 21, 2017 | clinicaltrials |
| NCT03376737 | Study of Apatinib as the Maintenance Therapy in Advanced Lung Adenocarcinoma | unknown | Phase 2 | 120 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 18, 2017 | clinicaltrials |
| NCT03135977 | Apatinib and Etoposide as the Maintenance Therapy in Extensive-stage Small Cell Lung Cancer After First-line Chemotherapy | unknown | Phase 2 | 36 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Dec 7, 2017 | clinicaltrials |
| NCT03201146 | Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC | unknown | Phase 1 / Phase 2 | 48 | West China HospitalOTHER | 1 | Nov 17, 2017 | clinicaltrials |
| NCT03341494 | EGFR Mutation Positive NSCLC Patients With Gefitinib and Thalidomide | unknown | Phase 2 | 128 | Fujian Cancer HospitalOTHER_GOV | 1 | Nov 14, 2017 | clinicaltrials |
| NCT02499614 | Crizotinib in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or ROS1 Translocation (METROS)(METROS) | unknown | Phase 2 | 80 | Fondazione Ricerca TraslazionaleOTHER | 1 | Oct 25, 2017 | clinicaltrials |
| NCT02995187 | Study of Apatinib as Third-line and Later Therapy in Patients With Small Cell Lung Cancer (SCLC) | unknown | Phase 2 | 25 | Chinese Academy of Medical SciencesOTHER | 1 | Sep 7, 2017 | clinicaltrials |
| NCT02423590 | Study of Gemcitabine/Carboplatin First-line Chemotherapy +/- Apatorsen in Advanced Squamous Cell Lung Cancers | unknown | Phase 2 | 140 | Queen Mary University of LondonOTHER | 1 | Aug 22, 2017 | clinicaltrials |
| NCT02515435 | The Efficacy and Safety of Apatinib in Heavily Pretreated Advanced Non-squamous Non-small Cell Lung Cancer | unknown | Phase 2 | 40 | Tongji UniversityOTHER | 1 | Aug 18, 2017 | clinicaltrials |
| NCT03065764 | 89Zr-labeled Pembrolizumab in Patients With Non-small-cell Lung Cancer | unknown | Phase 2 | 10 | Amsterdam UMC, location VUmcOTHER | 1 | Aug 17, 2017 | clinicaltrials |
| NCT03219554 | A Phase II Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumor | unknown | Phase 2 | 33 | Samsung Medical CenterOTHER | 1 | Aug 2, 2017 | clinicaltrials |
| NCT03219762 | Study of Nab-paclitaxel in Sensitive and Refractory Relapsed SCLC(Nabster) | unknown | Phase 2 | 65 | Gruppo Oncologico Italiano di Ricerca ClinicaOTHER | 1 | Jul 26, 2017 | clinicaltrials |
| NCT03205930 | Neo-MASCT Immunotherapy for Advanced NSCLC. | unknown | Phase 1 / Phase 2 | 20 | The First People's Hospital of LianyungangOTHER | 1 | Jul 5, 2017 | clinicaltrials |
| NCT03153358 | Icotinib Combined With SBRT for Patients With Metastatic Non-squamous NSCLC With EGFR Mutation | unknown | Phase 2 | 60 | Sichuan Cancer Hospital and Research InstituteOTHER | 0 | May 16, 2017 | clinicaltrials |
| NCT01963195 | Evaluation of the High Dose of Icotinib in Advanced Lung Cancer Patients After Failure of Target Therapy | unknown | Phase 2 | 30 | Anhui Medical UniversityOTHER | 1 | May 8, 2017 | clinicaltrials |
| NCT03123445 | Endostar First-line Treatment of Advanced NSCLC | unknown | Phase 2 | 150 | China Medical University, ChinaOTHER | 0 | Apr 21, 2017 | clinicaltrials |
| NCT03123484 | β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant NSCLC | unknown | Phase 2 | 80 | China Medical University, ChinaOTHER | 0 | Apr 21, 2017 | clinicaltrials |
| NCT02844114 | Clinical Study of Ganoderma Lucidum Spore Combined With Chemotherapy(LCKY2015-21(x)) | unknown | Phase 2 | 60 | Gao YajieOTHER | 1 | Mar 31, 2017 | clinicaltrials |
| NCT02714608 | A Study of Ginsenoside H Dripping Pills for Advanced Non-Small Cell Lung Cancer (NSCLC) | unknown | Phase 2 | 144 | Tasly Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 21, 2017 | clinicaltrials |
| NCT03074864 | Targeted Treatment With Intercalated Radiotherapy in EGFR-mutant IIIA/IIIB NSCLC(TREND) | unknown | Phase 2 / Phase 3 | 90 | Guangdong Provincial People's HospitalOTHER | 1 | Mar 9, 2017 | clinicaltrials |
| NCT01869023 | Phase II Study of Six Hours Low Dose Gemcitabine Plus Cisplatin in the Treatment for Advanced Pleural Mesothelioma | unknown | Phase 2 | 26 | Instituto Nacional de Cancerologia de MexicoOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT01980472 | Chemotherapy Plus Bevacizumab in Elderly Non-small Cell Lung Cancer Patients | unknown | Phase 2 | 50 | Grupo de Investigación y Divulgación OncológicaOTHER | 1 | Feb 27, 2017 | clinicaltrials |
| NCT02974933 | Apatinib Mesylate Combined With Pemetrexed in the Treatment of Pretreated Advanced Non-squamous Non-small Cell Lung Cancer | unknown | Phase 2 | 48 | Wuling OuOTHER | 1 | Feb 17, 2017 | clinicaltrials |
| NCT03053856 | Adjuvant Pembrolizumab in N2 Positive Non-small Cell Lung Cancer Patients | unknown | Phase 2 | 37 | Samsung Medical CenterOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT03050437 | A Study Comparing Pemetrexed Plus Cisplatin Versus Pemetrexed Alone in NSCLC Patients Who Have Progressed on First Line EGFR-TKI | unknown | Phase 2 | 96 | Samsung Medical CenterOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT03047525 | Study of DC-CTL Combined With CIK for Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 200 | Xiaoyi HuangOTHER | 1 | Feb 9, 2017 | clinicaltrials |
| NCT01714908 | Phase II Study of Erlotinib With Concurrent Radiotherapy in Unresectable NSCLC With Activating Mutation of EGFR in Exon 19 or 21(RECEL) | unknown | Phase 2 | 100 | Jinming YuOTHER | 1 | Feb 7, 2017 | clinicaltrials |
| NCT01744925 | Icotinib at Different Doses in Second-line Treatment for Non-small Cell Lung Cancer Patients With Wild Type EGFR | unknown | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 7, 2017 | clinicaltrials |
| NCT02370017 | Combined Effect of Natural Killer Cell and Doublet Chemotherapy in Advanced NSCLC as the 1st Line Treatment(ANKL-2) | unknown | Phase 2 | 68 | The Catholic University of KoreaOTHER | 1 | Feb 3, 2017 | clinicaltrials |
| NCT02967497 | Clinical Study of YQ1 Plus Cisplatin-based Chemotherapy in Advanced NSCLC EGFR Wild Type | unknown | Phase 2 | 56 | Taipei Veterans General Hospital, TaiwanOTHER_GOV | 0 | Jan 2, 2017 | clinicaltrials |
| NCT03002844 | EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism | unknown | Phase 2 | 50 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Dec 28, 2016 | clinicaltrials |
| NCT02029209 | To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer | unknown | Phase 2 / Phase 3 | 110 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Dec 16, 2016 | clinicaltrials |
| NCT02839954 | CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT02587689 | Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor | unknown | Phase 1 / Phase 2 | 20 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 5, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Apr 9, 2018source: clinicaltrials